Abstract

Background: Chronic low back ache (LBA) is one of the commonest and expensive ailments of youngsters with ambiguous pathophysiology leading to a signicant loss of productivity. Studies established that the vitamin D is a proven anabolic hormone for the entire musculoskeletal system. This study was designed to evaluate the differences in outcomes with various oral formulations of vitamin D available in the market. This Methodology: study is a randomised, prospective, open label analytical study of a cohort of patients with LBA and hypovitaminosis D from June 2022 to August 2022. Patients were sequentially randomized to one of the three treatment subgroups (Granule group, Nano Syrup group, Soft gel capsule group) named after the vit.D formulation they received after establishment of clinical, radiological and biochemical eligibility. Total number of 145 subjects were screened, among them 119 subjects were eligible and 87 have completed the study. Vitamin D supplementation of 60,000 IUs per dose for ten consecutive days (pulse-D therapy) was given in form of granule (1 g sachet) or nano syrup using aqueous nanotechnology (5 mL bottle) or soft gel capsule. Adverse drug reaction recording chart was provided to all patients and was reviewed regularly. The patient's weight was measured on day 0, week 3, week 6, week 9 and week 12. Hypovitaminosis D is a potential Results: causative factor for LBA in addition to the other known factors. The results obtained with nano syrup formulation were signicantly better compared to other formulations. Vitamin D can play an important role in pathogenesis and treatment of LBA. Nano Conclusion: formulations developed with aqueous technology have shown enhanced stability, water solubility, bioavailability, signicantly better improvement in vitamin D level and functional outcome in low back pain

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call